Teva upskilling of UK sterile site could lead to loss of 80 jobs

By Dan Stanton

- Last updated on GMT

Teva upskilling of UK sterile site could lead to loss of 80 jobs

Related tags Multiple sclerosis

Up to 80 UK sterile manufacturing jobs could be lost as part of a technical overhaul at a Teva site near Liverpool.

Teva’s Runcorn facility, near Liverpool in the UK, makes sterile products for use in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), primarily for export to the US.

Denise Bradley a spokesperson for the generic drugmaker told us the site is being assessed as part an ongoing reassessment of it pharmaceutical production network.

“The transformation we are undertaking requires investment in the skills and capabilities of our employees on the Runcorn site, building their technical expertise, and increasing the number of specialist roles in order to support the greater use of technology and automation now required in complex drug process development and manufacture,”​ she told

The plans would involve the potential loss of around 80 positions, she continued, though around twenty new specialist roles would be created, “reflecting the overall upskilling of the site.”

She added: “During the consultation period Teva will endeavour to mitigate the number of roles potentially lost and wherever possible to source suitable alternative redeployment opportunities within Teva for colleagues at risk of redundancy.”

Teva has been restructuring since 2013​, looking at saving around $2bn annually by 2017. The firm has also been resolute about investing in its complex generics​ production network and specialist technology platforms.

Among the drugs made at Runcorn, Bradley said, is a Teva leading medicine for the treatment of multiple sclerosis (MS).”

Teva’s blockbuster​ specialty MS drug Copaxone (glatiramer acetate inection) lost its exclusivity in 2014 but since then the firm has seen a thrice-weekly reformulation of the product approved by the US FDA.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more